Please login to the form below

Not currently logged in
Email:
Password:

ADC

This page shows the latest ADC news and features for those working in and with pharma, biotech and healthcare.

FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer

FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer

Tivdak – which was granted priority review by the FDA in April – is an antibody-drug conjugate composed of Genmab’s human monoclonal antibody and Seagen’s ADC technology involving monomethyl auristatin ... The ADC is directed to tissue factor, a

Latest news

More from news
Approximately 3 fully matching, plus 87 partially matching documents found.

Latest Intelligence

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    One such example is through the development of antibody-drug conjugates (ADC) – monoclonal antibodies attached to biologically active cytotoxic drugs. ... The FDA recently granted accelerated approval for the ADC trastuzumab-deruxtecan in patients with

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2. ... Kadcyla, the only other anti-HER2 ADC in this market, is a direct competitor and differentiation versus this established drug will be key.

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer therapy Herceptin (trastuzumab) with a cell-killing chemotherapy component designed to improve its ability ... Roche already has a

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    In addition to traditional antibodies, the pipeline also includes antibody drug conjugates (ADCs), bispecific antibodies created from its DuoBody technology platform, and antibodies created with its HexaBody technology.

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... As an ADC IMMU-132 contains SN-38,

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes. ... Dr Dave Simpson, chief executive officer of Glythera, said: “Robert Lutz’s

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    His experience in advancing scientific discoveries from the lab to commercialisation will be invaluable in helping us fully exploit our unique ADC platform, both in the development of our proprietary product

  • ADC Therapeutics expands team ADC Therapeutics expands team

    Appointments preceed its first antibody drug conjugate trials. ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Michael Forer, CEO of ADC Therapeutics, said:

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    conjugates (ADCs) for cancer. .

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • A MERGER THAT MATTERS

    Pegasus –the fifth largest healthcare agency in the UK –has merged with fellow Ashfield Health agencies Ashfield Digital and Creative (ADC) and Cambridge Biomarketing to form  Mind Matter, a ‘global creative

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...